Skip to main content
Top
Published in: Supportive Care in Cancer 12/2009

01-12-2009 | Original Article

Prevalence of emotional distress in newly diagnosed lung cancer patients

Authors: Tracy Steinberg, Michelle Roseman, Goulnar Kasymjanova, Sarah Dobson, Lucie Lajeunesse, Esther Dajczman, Harvey Kreisman, Neil MacDonald, Jason Agulnik, Victor Cohen, Zeev Rosberger, Martin Chasen, David Small

Published in: Supportive Care in Cancer | Issue 12/2009

Login to get access

Abstract

Goals of work

Distress is defined by the National Comprehensive Cancer Network as a multifactorial unpleasant emotional experience of a psychological, social, and/or spiritual nature that may interfere with the ability to cope effectively with cancer. We investigated the prevalence and associated symptoms of distress in newly diagnosed lung cancer patients.

Patients and methods

Between November 2005 and July 2007, 98 newly diagnosed lung cancer patients completed an assessment. The Distress Thermometer (DT) and Edmonton Symptom Assessment Scale (ESAS) were used as screening tools.

Main results

Fifty (51%) patients reported clinically significant distress (≥4) on the DT. Of those, 26 (52%) patients reported high levels of depression, nervousness, or both on ESAS. The remaining 24 (48%) patients had elevated levels of distress but no significant depression or nervousness. A correlation between the DT and the total ESAS score was observed (Pearson correlation = 0.46). The ten items of the ESAS together explained 46% of the variability in DT scores. The depression and nervousness ESAS items were significant predictors of DT score (p < 0.01 for both items). However, once the two psychosocial items, depression and nervousness, were removed from the total ESAS score, leaving only physical symptoms and the sleeplessness item, the predictive power of the model decreased to R² = 0.12.

Conclusions

The prevalence of distress in lung cancer patients is high. The DT appears to discriminate between physical and emotional distress. This easily measured score may determine which patients require further intervention for emotional distress.
Literature
3.
go back to reference World Health Organization International Agency for Research on Cancer (IARC) (2008) World Cancer Report. IARC, Lyon World Health Organization International Agency for Research on Cancer (IARC) (2008) World Cancer Report. IARC, Lyon
4.
go back to reference National Comprehensive Cancer Network. NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology. 2008. National Comprehensive Cancer Network. NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology. 2008.
6.
7.
go back to reference Holland J, Bultz B (2007) The NCCN guideline for distress management: a case for making distress the sixth vital sign. J Natl Compr Canc Netw 5(1):3–7PubMed Holland J, Bultz B (2007) The NCCN guideline for distress management: a case for making distress the sixth vital sign. J Natl Compr Canc Netw 5(1):3–7PubMed
10.
go back to reference Bruera E et al (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed Bruera E et al (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed
13.
go back to reference Philip J et al (1998) Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. Support Care Cancer 6(6):539–541. doi:10.1007/s005200050212 CrossRefPubMed Philip J et al (1998) Concurrent validity of the modified Edmonton Symptom Assessment System with the Rotterdam Symptom Checklist and the Brief Pain Inventory. Support Care Cancer 6(6):539–541. doi:10.​1007/​s005200050212 CrossRefPubMed
Metadata
Title
Prevalence of emotional distress in newly diagnosed lung cancer patients
Authors
Tracy Steinberg
Michelle Roseman
Goulnar Kasymjanova
Sarah Dobson
Lucie Lajeunesse
Esther Dajczman
Harvey Kreisman
Neil MacDonald
Jason Agulnik
Victor Cohen
Zeev Rosberger
Martin Chasen
David Small
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 12/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0614-6

Other articles of this Issue 12/2009

Supportive Care in Cancer 12/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine